An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
GordonMD Global Investments LP announces joint investment in Radionetics Oncology
Positive
GordonMD Global Investments LP has invested in a private placement financing for Radionetics Oncology
Radionetics Oncology focuses on the discovery and development of novel radiotherapeutics for oncology treatment
Market research reports predict the radiopharmaceutical market to reach $12.6 billion by 2027
Radionetics Oncology uses small molecule targeting to deliver radioisotopes to cancer cells
Radionetics Oncology is advancing a pipeline of small molecule radioligands for various cancers
Negative
None.
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--
Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financing for Radionetics Oncology. Radionetics Oncology, a clinical stage pharmaceutical company spun out of Crinetics (Nasdaq: CRNX) in 2021, focuses on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. GordonMD® joins Frazier Healthcare, 5AM Ventures, and Crinetics Pharmaceuticals as investors in Radionetics.
According to commercially available market research reports, the market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. Radionetics Oncology’s platform technology uses small molecule targeting to deliver radioisotopes to a broad range of cancers by binding selectively to receptors that are overexpressed on tumors. This small molecule technology attempts to address the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. Radionetics Oncology is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer.
“I believe Radionetics Oncology presents a unique investment opportunity. The company leverages novel targets and the power of radiopharmaceuticals for the treatment of cancer,” said Dr. Gordon, who is also a Board of Directors Observer for Radionetics. “Radionetics just launched an exciting clinical program for adrenocortical carcinoma, which has a high unmet need with no new therapeutics approved since 1970.”
GordonMD® Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with 13+ years of buy-side experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan. It currently provides investment management and administrative services to a hedge fund investing primarily in publicly traded companies as well as to two private equity funds.
THIS PRESS RELEASE IS INTENDED FOR INFORMATIONAL PURPOSES ONLY. THIS IS NOT AN OFFER OR SOLICITATION WITH RESPECT TO THE PURCHASE OR SALE OF ANY FUND OR SECURITY.
GordonMD Global Investments LP, Frazier Healthcare, 5AM Ventures, and Crinetics Pharmaceuticals have jointly invested in Radionetics Oncology.
What is Radionetics Oncology's focus?
Radionetics Oncology focuses on the discovery and development of novel radiotherapeutics for the treatment of various cancers.
What is the predicted market size for radiopharmaceuticals?
According to market research reports, the market for radiopharmaceuticals is expected to reach $12.6 billion by 2027.
How does Radionetics Oncology deliver radioisotopes to cancer cells?
Radionetics Oncology uses small molecule targeting to deliver radioisotopes to cancer cells by selectively binding to receptors that are overexpressed on tumors.
What is Radionetics Oncology's pipeline focused on?
Radionetics Oncology is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of various cancers.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
